Marshall Wace North America’s PTC Therapeutics PTCT Stock Holding History

Marshall Wace North America’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-97,635	Closed	-$4.62M	–	1708
2021 Q1	$4.62M	Buy	+97,635	New	+$5.8M	0.02%	589
2020 Q3	–	Sell	-16,908	Closed	-$858K	–	1426
2020 Q2	$858K	Buy	+16,908	New	+$831K	0.01%	795
2020 Q1	–	Sell	-2,509	Closed	-$120K	–	1525
2019 Q4	$120K	Buy	+2,509	New	+$107K	﹤0.01%	1039
2019 Q2	–	Sell	-662,587	Closed	-$24.9M	–	1528
2019 Q1	$24.9M	Buy	662,587 +293,495	+80%	+$9.85M	0.18%	124
2018 Q4	$12.7M	Sell	369,092 -73,768	-17%	-$2.65M	0.12%	145
2018 Q3	$20.8M	Sell	442,860 -1,267,114	-74%	-$52.4M	0.14%	137
2018 Q2	$57.7M	Buy	1,709,974 +1,048,803	+159%	+$32.7M	0.33%	71
2018 Q1	$17.9M	Buy	+661,171	New	+$16.8M	0.09%	261
2017 Q4	–	Sell	-61,745	Closed	-$1.24M	–	1562
2017 Q3	$1.24M	Buy	+61,745	New	+$1.21M	0.01%	905
2013 Q4	$373K	Buy	22,000 +2,000	+10%	+$35.2K	0.01%	566
2013 Q3	$429K	Buy	+20,000	New	+$348K	0.01%	468

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marshall Wace North America's PTCT Position: Q2 2021 in Review

Marshall Wace North America sold out of PTC Therapeutics (PTCT) in Q2 2021, closing a stake of 97,635 shares — an estimated $4.62M sold.

Marshall Wace North America first reported a position in PTCT in Q3 2013 and held it in 11 quarters. The position peaked at $57.7M in Q2 2018. 182 funds tracked by Wall St. Rank hold PTCT as of Q2 2021.

Marshall Wace North America reported no remaining PTC Therapeutics position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 97,635 PTC Therapeutics shares in Q2 2021, an estimated $4.62M.
Marshall Wace North America first reported a position in PTC Therapeutics in Q3 2013 and held it in 11 quarters.
Marshall Wace North America's PTC Therapeutics position peaked at $57.7M in Q2 2018.
182 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.